PMC:7784786 / 124-1011
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
24 | 165-168 | Gene | denotes | CD6 | Gene:923 |
25 | 394-399 | Gene | denotes | IFN-γ | Gene:3458 |
26 | 401-405 | Gene | denotes | IL-6 | Gene:3569 |
27 | 410-415 | Gene | denotes | TNF-α | Gene:7124 |
28 | 592-596 | Gene | denotes | IL-6 | Gene:3569 |
29 | 159-164 | Species | denotes | human | Tax:9606 |
30 | 489-497 | Species | denotes | patients | Tax:9606 |
31 | 623-631 | Species | denotes | patients | Tax:9606 |
32 | 650-658 | Species | denotes | patients | Tax:9606 |
33 | 107-117 | Chemical | denotes | Itolizumab | MESH:C000597346 |
34 | 511-521 | Chemical | denotes | itolizumab | MESH:C000597346 |
35 | 562-572 | Chemical | denotes | Itolizumab | MESH:C000597346 |
36 | 3-11 | Disease | denotes | COVID-19 | MESH:C000657245 |
37 | 290-299 | Disease | denotes | psoriasis | MESH:D011565 |
38 | 465-479 | Disease | denotes | critically ill | MESH:D016638 |
39 | 480-488 | Disease | denotes | COVID-19 | MESH:C000657245 |
40 | 843-851 | Disease | denotes | COVID-19 | MESH:C000657245 |
41 | 877-886 | Disease | denotes | mortality | MESH:D003643 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T2 | 30-55 | Phenotype | denotes | cytokine-release syndrome | http://purl.obolibrary.org/obo/HP_0033041 |
T3 | 290-299 | Phenotype | denotes | psoriasis | http://purl.obolibrary.org/obo/HP_0003765 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T3 | 0-106 | Sentence | denotes | In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. |
T4 | 107-200 | Sentence | denotes | Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. |
T5 | 201-300 | Sentence | denotes | The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. |
T6 | 301-416 | Sentence | denotes | Its effect is associated with the reduction of pro-inflammatory cytokines release, including IFN-γ, IL-6 and TNF-α. |
T7 | 417-561 | Sentence | denotes | Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. |
T8 | 562-632 | Sentence | denotes | Itolizumab was able to reduce IL-6 concentrations in all the patients. |
T9 | 633-732 | Sentence | denotes | Two of the three patients showed respiratory and radiological improvement and were fully recovered. |
T10 | 733-887 | Sentence | denotes | We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality. |